Are overexpressed alternative survivin transcripts in human bladder cancer suitable targets for siRNA-mediated in vitro inhibition?

International Journal of Oncology

Volumn 30, Issue 6, 2007, Pages 1317-1324

  Wuttig, D ^a   Kunze, D ^a   Fuessel, S ^a   Toma, M ^a   Stade, J ^a   Kotzsch, M ^a   Kappler, M ^b   Taubert, H ^b   Schwenzer, B ^a   Baretton, G ^a   Hakenberg, O W ^a   Meye, A ^a   Wirth, M P ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

BCa; Small interfering RNAs; Survivin 2B; Survivin Ex3

Indexed keywords

ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; ISOPROTEIN; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN; SMALL INTERFERING RNA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; APOPTOSIS; ARTICLE; BIOSYNTHESIS; BLADDER TUMOR; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; METABOLISM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ALTERNATIVE SPLICING; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; HUMANS; IMMUNOHISTOCHEMISTRY; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; URINARY BLADDER NEOPLASMS;

EID: 34447275011     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.6.1317     Document Type: Article

References (43)

1. Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3: 46-54, 2003. (Pubitemid 37328886)
2. Reed JC: The survivin saga goes in vivo. J Clin Invest 108: 965-969, 2001.
3. Dohi T, Okada K, Xia F, et al: An IAP-IAP complex inhibits apoptosis. J Biol Chem 279: 34087-34090, 2004.
4. Dohi T, Beltrami E, Wall NR, Plescia J and Altieri DC: Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 114: 1117-1127, 2004.
5. Li F and Ling X: Survivin study: an update of 'What is the next wave?'. J Cell Physiol 208: 476-486, 2006.
6. Vader G, Kauw JJ, Medema RH and Lens SM: Survivin mediates targeting of the chromosomal passenger complex to the centromere and midbody. EMBO Rep 7: 85-92, 2006.
7. Carvalho A, Carmena M, Sambade C, Earnshaw WC and Wheatley SP: Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. L Cell Sci 116: 2987-2998, 2003. (Pubitemid 36926987)
8. Zaffaroni N, Pennati M and Daidone MG: Survivin as a target for new anticancer interventions. J Cell Mol Med 9: 360-372, 2005.
9. Li F: Role of survivin and its splice variants in tumorigenesis. Br J Cancer 92: 212-216, 2005.
10. Monzo M, Rosell R, Felip E, et al: A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 17: 2100-2104, 1999.
11. Kappler M, Koehler T, Kampf C, et al: Increased survivin transcript levels: an independent negative predictor of survival in soft tissue sarcoma patients. Int J Cancer 95: 360-363, 2001.
12. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56: 106-130, 2006.
13. Weikert S, Christoph F, Schrader M, Krause H, Miller K and Mueller M: Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer 116: 100-104, 2005. (Pubitemid 40827761)
14. Wu Y, Wang G, Wei J and Wen X: Survivin protein expression positively correlated with proliferative activity of cancer cell in bladder cancer. Indian J Med Sci 59: 235-242, 2005.
15. Ku JH, Kwak C, Lee HS, Park HK, Lee E and Lee SE: Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. J Urol 171: 631-635, 2004.
16. Moussa O, Abol-Enein H, Bissada NK, Keane T, Ghoneim MA and Watson DK: Evaluation of survivin reverse transcriptase-polymerase chain reaction for non-invasive detection of bladder cancer. J Urol 175: 2312-2316, 2006.
17. Duggan BJ, Gray S, Johnston SR, Williamson K, Miyake H and Gleave M: The role of antisense oligonucleotides in the treatment of bladder cancer. Urol Res 30: 137-147, 2002. (Pubitemid 36056658)
18. Fojo T and Bates S: Strategies for reversing drug resistance. Oncogene 22: 7512-7523, 2003.
19. Mahotka C, Wenzel M, Springer E, Gabbert HE and Gerharz CD: Survivin-ΔEx3 and survivin-2B. Two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 59: 6097-6102, 1999.
20. Caldas H, Honsey LE and Altura RA: Survivin 2α: a novel survivin splice variant expressed in human malignancies. Mol Cancer 4: 11-20, 2005.
21. Suga K, Yamamoto T, Yamada Y, Miyatake S, Nakagawa T and Tanigawa N: Correlation between transcriptional expression of survivin isoforms and clinicopathological findings in human colorectal carcinomas. Oncol Rep 13: 891-897, 2005.
22. Vegran F, Boidot R, Oudin C, Riedinger JM and Lizard-Nacol S: Distinct expression of survivin splice variants in breast carcinomas. Int J Oncol 27: 1151-1157, 2005.
23. Caldas H, Jiang Y, Holloway MP, Fangusaro J, Mahotka C, Conway EM and Altura RA: Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 24: 1994-2007, 2005.
24. Mahotka C, Liebmann J, Wenzel M, Suschek CV, Schmitt M, Gabbert HE and Gerharz CD: Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ 9: 1334-1342, 2002.
25. Chen J, Wu W, Tahir SK, et al: Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia 2: 235-241, 2000.
26. Xia C, Xu Z, Yuan X, et al: Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther 1: 687-694, 2002.
27. Lu X, Zheng Q and Xiong J: Effect of siRNA targeting survivin gene on the biological behavior of hepatocellular carcinoma. J Huazhong Univ Sci Technolog Med Sci 25: 48-50, 2005.
28. Cao C, Mu Y, Hallahan DE and Lu B: XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 23: 7047-7052, 2004. (Pubitemid 39319166)
29. Fuessel S, Kueppers B, Ning S, et al: Systematic in vitro evaluation of survivin directed antisense oligodeoxy-nucleotides in bladder cancer cells. J Urol 171: 2471-2476, 2004.
30. Ning S, Fuessel S, Kotzsch M, et al: siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol 25: 1065-1071, 2004.
31. Fuessel S, Herrmann J, Ning S, et al: Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxy-nucleotides and siRNA. Cancer Lett 232: 243-254, 2006.
32. Fukuda S, Foster RG, Porter SB and Pelus LM: The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. Blood 100: 2463-2471, 2002.
33. Ryan B, O'Donovan N, Browne B, et al: Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer. Br J Cancer 92: 120-124, 2005.
34. Span PN, Tjan-Heijnen VC, Heuvel JJ, De Kok JB, Foekens JA and Sweep FC: Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer? Clin Chem 52: 1693-1700, 2006.
35. Mahotka C, Krieg T, Krieg A, et al: Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer 100: 30-36, 2002.
36. Fangusaro R, Jiang Y, Holloway MP, et al: Survivin, Survivin-2B, and Survivin-deltaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. Br J Cancer 31: 359-365, 2005.
37. Taubert H, Kappler M, Bache M, et al: Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcoma patients. Oncogene 24: 5258-5261, 2005.
38. Belyanskaya LL, Hopkins-Donaldson S, Kurtz S, et al: Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int J Cancer 117: 755-763, 2005. (Pubitemid 41598826)
39. Williams NS, Gaynor RB, Scoggin S, et al: Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 9: 931-946, 2003.
40. Geller J, Petak I, Szucs KS, Nagy K, Tillman DM and Houghton JA: Interferon-gamma-induced sensitization of colon carcinomas to ZD9331 targets caspases, downstream of Fas, independent of mitochondrial signaling and the inhibitor of apoptosis survivin. Clin Cancer Res 9: 6504-6515, 2003. (Pubitemid 38035162)
41. Li JX, Zhou KY, Liang T and Zhang YF: Knockdown of survivin expression by small interfering RNA induces apoptosis in human breast carcinoma cell line MCF-7. Ai Zheng 24: 268-272, 2005.
42. Wagner M, Schmelz K, Wuchter C, Ludwig WD, Dorken B and Tamm I: In vivo expression of survivin and its splice variant survivin-2B: impact on clinical outcome in acute myeloid leukaemia. Int J Cancer 119: 1291-1297, 2006.
43. + channels in adrenal and pituitary during the stress hyporesponsive period of rat development. Endocrinology 147: 3961-3967, 2006.